We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Day One Biopharmaceuticals Inc | NASDAQ:DAWN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.15 | 0.94% | 16.03 | 13.75 | 16.81 | 16.35 | 15.79 | 16.14 | 487,828 | 01:00:00 |
From Jul 2023 to Jul 2024
By Colin Kellaher
Day One Biopharmaceuticals shares rose sharply Monday after the clinical-stage biopharmaceutical company said the U.S. Food and Drug Administration granted priority review to its application seeking approval of its lead product candidate.
Shares of the Brisbane, Calif., company were recently changing hands at $11.49, up 13%.
Day One is seeking an FDA green light for tovorafenib as a monotherapy in relapsed or progressive pediatric low-grade glioma, the most common brain tumor diagnosed in children.
The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.
Day One said there is currently no standard of care and no approved therapy for the vast majority of pediatric low-grade glioma patients in the relapsed setting.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 30, 2023 10:39 ET (14:39 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Day One Biopharmaceuticals Chart |
1 Month Day One Biopharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
